[HTML] mdpi.com

[HTML][HTML] Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi, P Viale… - Antibiotics, 2023 - mdpi.com
(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …
被引用次数：4 相关文章

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach …

M Gatti, M Rinaldi, T Tonetti… - Antibiotics (2079 …, 2023 - search.ebscohost.com
Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi, P Viale… - …, 2023 - search.proquest.com
Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi… - Antibiotics (Basel …, 2023 - europepmc.org
Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …
[HTML] nih.gov

[HTML][HTML] Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi, P Viale… - Antibiotics, 2023 - ncbi.nlm.nih.gov
Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi, P Viale… - ANTIBIOTICS, 2023 - cris.unibo.it
Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach …

M Gatti, M Rinaldi, T Tonetti… - Antibiotics (Basel …, 2023 - pubmed.ncbi.nlm.nih.gov
(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …
[PDF] unibo.it

[PDF][PDF] Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi, P Viale… - 2023 - cris.unibo.it
(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach …

M Gatti, M Rinaldi, T Tonetti, A Siniscalchi… - Antibiotics (Basel …, 2023 - europepmc.org
(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …